SARS-CoV-2 Subunit Vaccine and Microneedle Array Delivery System
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsAndrea Gambotto, Louis Falo, JR., Eun Kim
Life of this patent
Estimating the term…
Abstract
A recombinant coronavirus vaccine is provided. Methods of making and delivering the coronavirus vaccine also are provided. A microneedle array is provided, along with methods of making and using the microneedle array.
Claims23
A method of preventing infection with SARS-CoV-2, vaccinating a patient for SARS-CoV-2, or treating or reducing a symptom of a SARS-CoV-2 infection in a patient, comprising administering to the patient an amount of a composition, by a route of administration effective to induce an immune response to SARS-CoV-2, wherein said composition comprises a polypeptide comprising an immunogenic amino acid sequence of a SARS-CoV-2 spike protein or a conservative derivative thereof able to elicit an immune response to a SARS-CoV-2 spike protein, and optionally an amino acid sequence not from SARS-CoV-2, or a polypeptide having the sequence of SEQ ID NO:
- 2, of amino acids 1-661 of SEQ ID NO:
- 2, of a naturally-occurring variant thereof, or a derivative thereof having at least 95% sequence identity with amino acids 1-661 of SEQ ID NO:
- 2, or with SEQ ID NO:
- 2, and a pharmaceutically acceptable excipient.
A nucleic acid, comprising a gene for expressing a polypeptide having the sequence of SEQ ID NO:
- 2, of amino acids 1-661 of SEQ ID NO:
- 2, of a naturally-occurring variant thereof, or a derivative thereof having at least 95% sequence identity with amino acids 1-661 of SEQ ID NO:
- 2, or with SEQ ID NO:
- 2.
An immunogenic pharmaceutical composition for use in eliciting an immune response to SARS-CoV-2 in a patient, comprising a polypeptide having the sequence of SEQ ID NO:
- 2, amino acids 1-661 of SEQ ID NO:
- 2, a naturally-occurring variant thereof, or a derivative thereof having at least 95% sequence identity with amino acids 1-661 of SEQ ID NO:
- 2, and a pharmaceutically-acceptable excipient.
A microneedle array for use in eliciting an immune response to SARS-CoV-2 in a patient, comprising:
- a backing layer;
- and a plurality of microneedles, with a polypeptide having the sequence of SEQ ID NO:
- 2, amino acids 1-661 of SEQ ID NO:
- 2, a naturally-occurring variant thereof, or a derivative thereof having at least 95% sequence identity with amino acids 1-661 of SEQ ID NO:
- 2 incorporated into or onto the microneedle.
Dependencies are inferred from the claim text.